Catalyst
Monitor upcoming detailed results presentation and ongoing trials, especially the combination study with pembrolizumab and other novel combinations.
Date
June 24, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.